MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. - Wikidata - wikimedia - TriplyDB

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

http://www.wikidata.org/entity/Q39355055

about

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer MEK and PI3K inhibition in solid tumors: rationale and evidence to date Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers Adaptive resistance to targeted therapies in cancer Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Negative feedback regulation of the ERK1/2 MAPK pathway Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK Translating genomic profiling to gastrointestinal cancer treatment.Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Molecular markers predictive of chemotherapy response in colorectal cancer Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells A Probabilistic Boolean Network Approach for the Analysis of Cancer-Specific Signalling: A Case Study of Deregulated PDGF Signalling in GIST.Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

P2860

Q26747329-6DE96BC4-C84C-4696-9C7F-8BFD8B9F0D55 Q26775573-7B9EC3E7-B67C-4686-89EA-A0449FD43617 Q26781362-3104A771-8514-4E4F-AF9E-79E112CAAD01 Q26849316-262579E4-A769-4A8B-B9EF-6A6B8B058794 Q27853108-DC1850B7-7273-46DE-B010-6E0696CA3B92 Q28079202-7F136AD9-6786-423A-9504-F074BE411ADF Q28389726-5BBB0725-A65C-4E39-9FAC-0585F0CCE507 Q28540161-5209645F-463A-4042-A7DF-8A32FB93B4D1 Q28551145-3688E9B0-C2C4-4CB6-A2AE-58E5F6206C14 Q28833671-8766EAE6-CF46-4C27-9942-96FF2ADB6A60 Q28833740-E2B58520-A71C-41CF-8F61-C41602082063 Q30239109-230EC094-188C-4C96-BE29-2648A16A4F8D Q30275521-4E449E97-54A0-4278-A9C6-843F708EFE85 Q30371561-5CE7F271-C754-4EFE-8902-D38539744DCA Q33601653-CA3B3619-6226-4C72-8117-D90535A7FC55 Q33646519-7AAB6DF7-1B6B-44B2-A2C7-AAF2F02F801B Q33737298-36D9DCAE-8C96-4EBD-94FE-8E0C32A15AF6 Q34123525-8FFA9508-A4F3-4DB9-9EB0-A11CD98D18C8 Q34458117-3528BC07-E561-4E56-96FC-D44F2B944868 Q34466060-58EBE7D0-28BE-425F-8B7B-5220F796AB4A Q34505851-0F624F78-F14D-41D3-ACE3-400E42AD9F8D Q34625311-6637CAA9-8F1E-416C-91F3-9011EB3C2DA2 Q35000243-79F8F48B-6BA3-433A-85B2-2F119AF2D94F Q35657842-CB894424-6734-426F-809D-50AA71E6A2B9 Q35670413-75C81B3F-B47E-4E63-9819-5EFD9A041AD1 Q35675442-13151501-66F4-4D55-A99E-BEF253494689 Q35677661-47D6C639-DC2F-4AC6-B36E-20BD888D0759 Q35761956-AB151047-A6D2-400F-A0E8-9EBD8EDBD8E3 Q35775241-E3A5C76B-21A0-4C82-8AA1-BFC4E062D188 Q35950783-FC06BDF0-AB4D-498C-90D5-DB5DF190F7FC Q36032370-AE6D5FA5-F21F-419F-AE32-F0402AD3C28F Q36716682-9D582D98-D0C6-4724-82FF-EAC7A925E463 Q36763119-7F59FD62-094B-424C-A095-02BFEA93A265 Q36775204-42848A78-DA76-4739-8ABE-6DA699045B27 Q36917882-C047A34F-E689-4BCA-88CC-C450001BC06E Q37024819-2CCA619F-D9DD-4EA1-9AB5-DDD8A109EE29 Q37347999-41ADC4AF-EC34-4A9A-9847-74828D50A4B8 Q37349748-45C4C898-0AB1-41CF-97A8-B946FF7C944E Q37380418-9FAAD76C-FC99-4055-AD56-CE9364E5C671 Q37421439-E8335212-85C6-4470-8DFF-6BFBA176040C

P2860

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

http://www.wikidata.org/entity/Q39355055

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@en

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@nl

type

label

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@en

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@nl

prefLabel

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@en

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@nl

P1433

Q39355055-B8D46194-E31F-4BEF-BDC1-377AC3D94951

P1476

Q39355055-362FC3C2-178E-4423-AB2B-1112B6E5C916

P2093

Q39355055-39E95CA1-8289-41AE-86EC-2496153BD03B

Q39355055-6C258D4F-8809-4D80-A3DE-2F152E7148F2

Q39355055-95E37E5A-1E0B-4308-9B4B-9345F2C5AD25

Q39355055-B04DD748-A15B-4220-8124-86B002370766

Q39355055-B6FCF77F-7E0C-4F44-8D6C-389C4D6FBDB7

Q39355055-C65AAC9A-FC11-45B4-9635-547C7530AD01

Q39355055-DC93A1E6-65C1-4D0A-A9AD-328B653AF69C

P2860

Q39355055-028F2C38-A266-4163-B0DA-22278F538615

Q39355055-041A622A-B61E-4713-8CA9-F24EC7B31B28

Q39355055-0D4E3F05-92F4-47E0-B071-2209528AB9AA

Q39355055-15CD8FE2-E7A9-4BC1-A17C-C8AE3F973B5D

Q39355055-171AAEB7-12C8-432B-B70E-D2578A3BC049

Q39355055-2BAB6751-9407-407D-95D4-89DE742C42B1

Q39355055-2F3033B5-E8EE-41AB-A1FE-509DC7BC105A

Q39355055-497F83AA-7950-4481-B551-787EA8ED196A

Q39355055-4DB9D472-DBD9-489E-8655-5A612A717526

Q39355055-5AEE2D26-88AC-4D99-8340-35EAA3340A59

P304

Q39355055-5188A0DD-91F0-4A46-A5BD-A96317A09121

P31

Q39355055-6F90ABF1-57AB-4BCE-BFF0-F5CA46379BFA

P356

Q39355055-81E044F0-3B3E-4377-A687-3E75A52BB1A2

P407

Q39355055-BD28EF30-C9EF-406E-B090-1414728D6956

P433

Q39355055-DC2D2BC9-6CA3-48BB-9C90-B377A210D2D8

P478

Q39355055-4355B342-0138-4FC9-B8C8-4072D7A92403

P577

Q39355055-4D2E4065-D13F-44B9-BD36-FC089F76382A

P698

Q39355055-0414B42D-29E8-45CB-BE75-786A78751461

P932

Q39355055-DC12F195-C7A5-4558-A6B8-DCA794FFC17D

P356

0008-5472.CAN-11-3747

P1433

Cancer Research

P1476

MEK inhibition leads to PI3K/A ...... ve feedback on ERBB receptors.

@en

P2093

Alexa B Turke

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Carlotta Costa

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

John M Asara

http://www.w3.org/2001/XMLSchema#string

Rebecca Cook

http://www.w3.org/2001/XMLSchema#string

Youngchul Song

http://www.w3.org/2001/XMLSchema#string

P2860

An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Defining the role of mTOR in cancer

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy

P304

3228-3237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-3747

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22552284

http://www.w3.org/2001/XMLSchema#string

P932

3515079

http://www.w3.org/2001/XMLSchema#string